Amgen Inc. $AMGN Shares Sold by Vivaldi Capital Management LP

Vivaldi Capital Management LP decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.7% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 46,681 shares of the medical research company’s stock after selling 2,315 shares during the period. Amgen makes up about 2.3% of Vivaldi Capital Management LP’s investment portfolio, making the stock its 11th largest position. Vivaldi Capital Management LP’s holdings in Amgen were worth $16,425,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of AMGN. Dogwood Wealth Management LLC raised its position in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the period. Anfield Capital Management LLC lifted its stake in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares in the last quarter. Tower View Wealth Management LLC boosted its position in shares of Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after buying an additional 63 shares during the period. Manning & Napier Advisors LLC boosted its position in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares during the period. Finally, Olistico Wealth LLC acquired a new stake in shares of Amgen in the fourth quarter valued at about $33,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Weiss Ratings downgraded Amgen from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 15th. Royal Bank Of Canada restated a “positive” rating on shares of Amgen in a report on Thursday, June 18th. Morgan Stanley lowered their price objective on shares of Amgen from $340.00 to $333.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 8th. Cantor Fitzgerald reiterated a “neutral” rating and set a $350.00 price objective on shares of Amgen in a research note on Monday, July 6th. Finally, UBS Group boosted their target price on shares of Amgen from $400.00 to $420.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $356.62.

Amgen Stock Up 1.2%

Shares of NASDAQ AMGN opened at $376.04 on Friday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $391.29. The stock’s 50-day simple moving average is $351.28 and its 200-day simple moving average is $351.80. The firm has a market cap of $202.95 billion, a price-to-earnings ratio of 26.17, a PEG ratio of 3.76 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the business posted $4.90 earnings per share. Amgen’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 22.31 earnings per share for the current fiscal year.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.85% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.